These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7624943)

  • 21. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
    Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperfractionated total lymphoid irradiation and cyclophosphamide for preparation of previously transfused patients undergoing HLA-identical marrow transplantation for severe aplastic anemia.
    Castro-Malaspina H; Childs B; Laver J; Shank B; Brochstein J; Gillio A; Flomenberg N; Young J; Boulad F; Black P
    Int J Radiat Oncol Biol Phys; 1994 Jul; 29(4):847-54. PubMed ID: 8040033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Audit of peripheral stem cell transplantation for aplastic anemia in multitransfused infected patients.
    Seth T; Kanga U; Sood P; Sharma V; Mishra P; Mahapatra M
    Transplant Proc; 2012 May; 44(4):922-4. PubMed ID: 22564586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A clinical study of haploidentical transplantation using granulocyte colony-stimulating factor stimulating donor bone marrow].
    Chen H; Ji S; Wang H
    Zhonghua Nei Ke Za Zhi; 2001 Nov; 40(11):760-3. PubMed ID: 11930684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
    Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. rhGM-CSF after allogeneic bone marrow transplantation from unrelated donors: a pilot study of cyclosporine and prednisone as graft-versus-host disease prophylaxis.
    Nemunaitis J; Anasetti C; Bianco JA; Hasen J; Singer JW
    Leuk Lymphoma; 1993 Jun; 10(3):177-81. PubMed ID: 8220115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease.
    Russell JA; Woodman RC; Poon MC; Jones AR; Ruether BA
    Bone Marrow Transplant; 1994 Sep; 14(3):397-401. PubMed ID: 7994261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
    Liesveld J; Duerst R; Rapoport A; Constine L; Abboud C; Packman C; Wedow L; Zwetsch L; McKenna B; Linder T; Silverman W; Swift S; Rowe J; DiPersio J
    Bone Marrow Transplant; 1999 Sep; 24(5):511-6. PubMed ID: 10482935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Graft-versus-host disease prophylaxis with anti-T-cell monoclonal antibody OKT3, prednisone and methotrexate in allogeneic bone-marrow transplantation.
    Filipovich AH; Krawczak CL; Kersey JH; McGlave P; Ramsay NK; Goldman A; Goldstein G
    Br J Haematol; 1985 May; 60(1):143-52. PubMed ID: 3890926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic bone marrow transplantation with related donors other than HLA MLC-matched siblings, and the use of antithymocyte globulin, prednisone, and methotrexate for prophylaxis of graft-versus-host disease.
    Filipovich AH; Ramsay NK; Arthur DC; McGlave P; Kim T; Kersey JH
    Transplantation; 1985 Mar; 39(3):282-5. PubMed ID: 3156437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey.
    Sakai R; Taguri M; Oshima K; Mori T; Ago H; Adachi S; Morita S; Taniguchi S; Fukuda T; Ohashi K; Eto T; Miyamura K; Iwato K; Kobayashi N; Kanamori H; Morishima Y; Nagamura-Inoue T; Sakamaki H; Atsuta Y; Murata M
    Int J Hematol; 2016 Mar; 103(3):322-33. PubMed ID: 26800676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial.
    Mevorach D; Zuckerman T; Reiner I; Shimoni A; Samuel S; Nagler A; Rowe JM; Or R
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):58-65. PubMed ID: 24140121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Beelen DW; Quabeck K; Kaiser B; Wiefelspütz J; Scheulen ME; Graeven U; Grosse-Wilde H; Sayer HG; Schaefer UW
    Transplantation; 1990 Sep; 50(3):421-7. PubMed ID: 2402791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1.
    Ferrant A; Latinne D; Bazin H; Straetmans N; Cornet A; de la Parra B; Michaux JL
    Bone Marrow Transplant; 1995 Oct; 16(4):577-81. PubMed ID: 8528175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
    Gupta V; Ball SE; Yi QL; Sage D; McCann SR; Lawler M; Ortin M; Freires M; Hale G; Waldmann H; Gordon-Smith EC; Marsh JC
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):867-76. PubMed ID: 15570255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation.
    Iravani M; Mousavi A; Gholibeikian S; Bahar B; Samiee S; Ashouri A; Eghbal L; Ghavamzadeh A
    Bone Marrow Transplant; 2005 Jun; 35(11):1095-9. PubMed ID: 15821773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.